JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chu, X.-Y.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chu, X.-Y.
Right arrow Articles by Sugiyama, Y.

Vol. 288, Issue 2, 735-741, February 1999

Active Efflux of CPT-11 and Its Metabolites in Human KB-Derived Cell Lines1

Xiao-Yan Chu, Hiroshi Suzuki, Kaoru Ueda, Yukio Kato, Shin-Ichi Akiyama and Yuichi Sugiyama

Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan (X.-Y.C., H.S., K.U., Y.K., Y.S.); and Institute of Cancer Research, Kagoshima University, Kagoshima, Japan (S.A.)

To investigate the possible involvement of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), and/or other glutathione S-conjugate export pump (GS-X pump) family members on the active efflux of irinotecan [(7-ethyl-10-[4-(1-piperidino)-1-pipertidino)-1-piperidino]carbonyloxy camptothecin (CPT-11)] and its metabolites, as well as their contribution to the acquisition of resistance, we studied the uptake of CPT-11, its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) using membrane vesicles from human epidermoid KB-3-1-derived cell lines. These lines included KB-C2, C-A500, and KCP-4, which overexpress P-gp, MRP, and the unidentified GS-X pump, respectively. The carboxylate form of SN-38 exhibited significant ATP-dependent transport, with a Michaelis constant of 17 µM, into membrane vesicles from C-A500 but not from other cell lines. Among these KB-derived cells, significant ATP-dependent uptake of the carboxylate form of CPT-11 was only observed in KB-C2 vesicles. In addition, the uptake of the lactone and carboxylate forms of SN38-Glu into membrane vesicles from C-A500 and KB-C2, but not KCP-4, was ATP dependent, although the transport activity in C-A500 was much higher than that in KB-C2. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay revealed that the resistance of KB-C2 to CPT-11 and SN-38, compared with that of KB-3-1, was 6.3- and 6.8-fold, respectively; the corresponding figures for C-A500 were 12- and 27-fold, respectively, whereas those for KCP-4 were 2.3- and 20-fold, respectively. These results suggest that MRP and P-gp are involved in the active efflux of SN-38 and CPT-11, respectively, from human KB-derived cells. In addition, a difference in substrate specificity among GS-X pump members was demonstrated.

0022-3565/99/2882-0735$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
X.-X. Yang, Z.-P. Hu, A.-L. Xu, W. Duan, Y.-Z. Zhu, M. Huang, F.-S. Sheu, Q. Zhang, J.-S. Bian, E. Chan, et al.
A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor-{alpha} Inhibitor
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 82 - 104.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al.
Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination
J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. G. Azrak, J. Yu, L. Pendyala, P. F. Smith, S. Cao, X. Li, W. D. Shannon, F. A. Durrani, H. L. McLeod, and Y. M. Rustum
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors
Mol. Cancer Ther., May 1, 2005; 4(5): 843 - 854.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Breedveld, N. Zelcer, D. Pluim, O. Sonmezer, M. M. Tibben, J. H. Beijnen, A. H. Schinkel, O. van Tellingen, P. Borst, and J. H. M. Schellens
Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions
Cancer Res., August 15, 2004; 64(16): 5804 - 5811.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, et al.
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
N. Engl. J. Med., July 22, 2004; 351(4): 337 - 345.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Xu and M. A. Villalona-Calero
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
Ann. Onc., December 1, 2002; 13(12): 1841 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
F. R. Luo, P. V. Paranjpe, A. Guo, E. Rubin, and P. Sinko
Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1
Drug Metab. Dispos., July 1, 2002; 30(7): 763 - 770.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
C. D. Turner, S. Gururangan, J. Eastwood, K. Bottom, M. Watral, R. Beason, R. E. McLendon, A. H. Friedman, S. Tourt-Uhlig, L. L. Miller, et al.
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience
Neuro-oncol, April 1, 2002; 4(2): 102 - 108.
[Abstract] [PDF]

Home page
 The OncologistHome page
L. Bomgaars, S. L. Berg, and S. M. Blaney
The Development of Camptothecin Analogs in Childhood Cancers
Oncologist, December 1, 2001; 6(6): 506 - 516.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. P. Gamcsik, M. S. Kasibhatla, D. J. Adams, J. L. Flowers, O. M. Colvin, G. Manikumar, M. Wani, M. E. Wall, G. Kohlhagen, and Y. Pommier
Dual Role of Glutathione in Modulating Camptothecin Activity: Depletion Potentiates Activity, but Conjugation Enhances the Stability of the Topoisomerase I-DNA Cleavage Complex
Mol. Cancer Ther., November 1, 2001; 1(1): 11 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Larsen, C. Gilbert, G. Chyzak, S. Y. Plisov, I. Naguibneva, O. Lavergne, L. Lesueur-Ginot, and D. C. H. Bigg
Unusual Potency of BN 80915, a Novel Fluorinated E-ring Modified Camptothecin, toward Human Colon Carcinoma Cells
Cancer Res., April 1, 2001; 61(7): 2961 - 2967.
[Abstract] [Full Text]

Home page
 The OncologistHome page
M. L. Rothenberg
Irinotecan (CPT-11): Recent Developments and Future Directions-Colorectal Cancer and Beyond
Oncologist, February 1, 2001; 6(1): 66 - 80.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
X.-Y. Chu, Y. Kato, and Y. Sugiyama
Possible Involvement of P-Glycoprotein in Biliary Excretion of CPT-11 in Rats
Drug Metab. Dispos., April 1, 1999; 27(4): 440 - 441.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.